Cytiva collaborates with Bangalore Bioinnovation Centre to provide bioprocessing training programs to support the start-up ecosystem in India
Cytiva and Bangalore Bioinnovation Centre (BBC), a bio-incubation centre for startups, agreed to work together to support the start-up and academic ecosystems in the local biopharmaceutical industry by providing a platform for skills development and industry-oriented bioprocessing training program. The BBC is set up by the Karnataka Innovation Technology Society (KITS) and the Government of Karnataka with funding support from the Indian Government’s Department of Biotechnology (DBT).
India's biotechnology industry, estimated to reach 150 billion USD by 2025, expects to see the number of startups to grow from more than 4,000 to 10,0001.
The signing ceremony between Cytiva and BBC on Feb. 16.
The BBC is a world class incubation center with central instrumentation facility in a 10-acre campus. The center provides infrastructure support, skills development and assistance to start-up companies, ventures, and projects in the field to help conversion of innovative ideas and research into commercialization.
This collaboration aligns well in giving impetus to the innovation ecosystem by driving linkages between academia and industry.
Dr Jitendra, Managing Director, Bangalore Bioinnovation Centre says: “This collaboration will help create a training program catering to the distinct needs of the biopharma industry today.”
Vaggu Raghavendra Goud, General Manager of Cytiva South Asia, says: “Cytiva has been supporting the Indian biotechnology industry for more than 30 years. With the industry experiencing fast growth, the need for talent is increasing. This collaboration enables us to bring our global knowledge and expertise to support BBC, the local biotech companies and academia to fulfill the need for skilled talent.”
Talent is critical for all industries, but it is particularly critical for the biopharma industry given the complexity of the sector. According to Cytiva’s Global Biopharma Resilience Index, talent pool is the weakest link in the global biopharma industry. 65% of Indian respondents in the Biopharma Resilience Index say that sourcing talent in technology, manufacturing, and R&D is a substantial challenge. Thus, the demand for the collaboration is expected to be high.
###
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Media Contact
Iris Zhao
[email protected]